Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer with limited meaningful treatment options. NEPC lesions uniquely express delta-like ligand 3 (DLL3) on their cell surface. Taking advantage of DLL3 overexpression, we developed and evaluated lutetium-177 ((177)Lu)–labeled D...

Descripción completa

Detalles Bibliográficos
Autores principales: Korsen, Joshua A., Gutierrez, Julia A., Tully, Kathryn M., Carter, Lukas M., Samuels, Zachary V., Khitrov, Samantha, Poirier, John T., Rudin, Charles M., Chen, Yu, Morris, Michael J., Bodei, Lisa, Pillarsetty, Nagavarakishore, Lewis, Jason S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271187/
https://www.ncbi.nlm.nih.gov/pubmed/35759660
http://dx.doi.org/10.1073/pnas.2203820119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271187/
https://www.ncbi.nlm.nih.gov/pubmed/35759660
http://dx.doi.org/10.1073/pnas.2203820119

Ejemplares similares